Issue: 2018 > April > case report

Cholesterol embolisms as possible adverse drug reaction of direct oral anticoagulants

A.H.G. Muller-Hansma, C.R.G.M. Daemen-Gubbels, N.H. Schut
AbstractFull textPDF


The Netherlands Pharmacovigilance Centre Lareb has received two reports of cholesterol crystal embolisms associated with the use of a direct oral anticoagulant (DOAC). The European pharmacovigilance database contains several other cases concerning this association, and one report was published in the scientific literature. Cholesterol crystal embolisms were described in association with the use of several other antithrombotic drugs, although the role as an independent risk factor is not conclusive. The case series described in this article, indicates the possibility of an adverse drug reaction when a patient develops cholesterol crystal embolisms while using a DOAC.